Immix Biopharma, Inc. (IMMX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $11.92, IMMX has negative trailing earnings (P/E not meaningful) and an ROE of -38.44%. Market capitalisation stands at $648M.
Balance sheet quality for IMMX: current ratio of 10.0, net cash position of $99.3M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $11.92 |
| Market Cap | $648M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.29 |
| EV / EBITDA | -13.21 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -38.44% |
| Return on Invested Capital | -18.19% |
| Return on Assets | -16.69% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 25.13 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IMMX | Immix Biopharma, Inc. | $648M | 3.29 | -38.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | +0.93% |
| 3 months | +36.70% |
| Year-to-date | +127.92% |
| 1 year | +508.16% |
| 3 years | +349.81% |
52-Week Range
| 52-week High | $15.10 |
| 52-week Low | $1.94 |
| Avg Volume (90d) | 1.7M |
Related companies: ATOS · COYA · MGNX · ONCY · ORMP · PLRX · SRZN
Explore sector: Healthcare · Biotechnology
More sections of IMMX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks